Streetbeat News

Revenues

CTV

Innovid expects Q3 revenue to be between $40M and $42M, reflecting a year-over-year growth of 10% to 16%. The estimated revenue is $40.70M.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 11:45 am

FWRG

First Watch Restaurant confirms its FY24 total revenue growth of 17.0% to 19.0%, with adjusted EBITDA expected to be between $106.0 million and $112.0 million. The company plans capital expenditures of $125.0 million to $135.0 million, primarily for new restaurant projects and remodels.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 11:43 am

ADCT

ADC Therapeutics reported having $300.1 million in cash and cash equivalents as of June 30, which extends their expected cash runway into mid-2026.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 11:37 am

HLMN

Hillman Solutions has revised its 2024 revenue guidance to a range of $1.44 billion to $1.48 billion, down from the previous range of $1.475 billion to $1.555 billion. The company also provided a free cash flow estimate of $100 million to $120 million.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 11:37 am

SGRY

Surgery Partners (NASDAQ:SGRY) reported Q2 earnings of $0.21 per share, beating the analyst estimate of $0.20. Sales were $762.10 million, surpassing the $735.57 million estimate. Despite the earnings beat, EPS decreased by 25% year-over-year.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 11:36 am

BVS

Bioventus has raised its 2024 financial guidance, now expecting net sales of $557M-$567M and adjusted EPS of $0.36-$0.42, reflecting significant increases from previous estimates.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 11:35 am

ML

MoneyLion has projected its FY24 revenue to be between $525 million and $535 million, surpassing the estimated $522.425 million.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 11:35 am

OGN

Organon has updated its 2024 revenue guidance to $6.25B-$6.45B, aligning with prior guidance and close to the consensus of $6.407B. Other financial metrics remain largely unchanged, with a slight increase in R&D expenses.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 11:35 am

ML

MoneyLion has projected its Q3 revenue to be between $133 million and $138 million, surpassing the estimated $127.025 million.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 11:35 am

KPTI

Karyopharm Therapeutics has revised its FY24 total revenue outlook from a range of $140M - $160M to $145M - $160M, with an estimated revenue of $145.44M.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 11:35 am